Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted drug tested against chemo for shrinking ovarian tumors before surgery

NCT ID NCT06964165

Terminated Disease control Sponsor: Tesaro, Inc. Source: ClinicalTrials.gov ↗

Summary

This study aimed to see if a targeted drug called niraparib works better than standard chemotherapy to shrink tumors before surgery in people with advanced ovarian cancer that has specific genetic features. It involved 36 participants with newly diagnosed stage III or IV ovarian cancer who had already completed one cycle of standard chemotherapy. The trial was terminated early and did not complete its planned enrollment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    San Francisco, California, 94115, United States

  • GSK Investigational Site

    Miami, Florida, 33136, United States

  • GSK Investigational Site

    Tampa, Florida, 33606, United States

  • GSK Investigational Site

    Scarborough, Maine, 04074, United States

  • GSK Investigational Site

    Boston, Massachusetts, 02114, United States

  • GSK Investigational Site

    St Louis, Missouri, 63141, United States

  • GSK Investigational Site

    New York, New York, 10029, United States

  • GSK Investigational Site

    New York, New York, 77030, United States

  • GSK Investigational Site

    Rochester, New York, 14642, United States

  • GSK Investigational Site

    Sioux Falls, South Dakota, 57105, United States

  • GSK Investigational Site

    Seattle, Washington, 98104, United States

  • GSK Investigational Site

    Ottawa, Ontario, K1H 8L6, Canada

  • GSK Investigational Site

    Montreal, Quebec, H2X 0A9, Canada

  • GSK Investigational Site

    Montreal, Quebec, H4A 3J1, Canada

  • GSK Investigational Site

    A Coruña, ES, 15006, Spain

  • GSK Investigational Site

    Madrid, ES, 28027, Spain

  • GSK Investigational Site

    Madrid, ES, 28033, Spain

  • GSK Investigational Site

    Madrid, ES, 28050, Spain

  • GSK Investigational Site

    Madrid, ES, 28223, Spain

  • GSK Investigational Site

    Málaga, ES, 29001, Spain

  • GSK Investigational Site

    Pamplona, ES, 31008, Spain

Conditions

Explore the condition pages connected to this study.

OVARIAN NEOPLASMS